The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy

Table 2

Association (count (%)) between various parameters of 153 breast cancer cases and RCB classes (chi-square test).

Breast cancer parameters	RCB				value
	PCR	Non-PCR groups
	RCB 0	RCB I	RCB II	RCB III
	Count (%)	Count (%)	Count (%)	Count (%)
Type
IDC+	23 (18.7%)	4 (3.3%)	44 (35.8%)	52 (42.3%)	0.340
Non-IDC	6 (20.0%)	1 (3.3%)	6 (20.0%)	17 (56.7%)
Grade
I	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	<0.001
II	10 (11.6%)	3 (3.5%)	21 (24.4%)	52 (60.5%)
III	19 (31.1%)	2 (3.3%)	26 (42.6%)	14 (23.0%)
LVI+
Yes	1 (1.1%)	0 (0.0%)	21 (23.6%)	67 (75.3%)	<0.001
No	28 (43.8%)	5 (7.8%)	29 (45.3%)	2 (3.1%)
M. subtype+
Luminal	2 (2.6%)	1 (1.3%)	21 (27.6%)	52 (68.4%)	<0.001
TNBC+	27 (35.1%)	4 (5.2%)	29 (37.7%)	17 (22.1%)
Lymphocyte groups
Lymphocyte poor	4 (14.8%)	1 (3.7%)	9 (33.3%)	13 (48.1%)	0.623
Intermediate group	9 (13.6%)	2 (3.0%)	22 (33.3%)	33 (50.0%)
Lymphocytic predominant	16 (26.7%)	2 (3.3%)	19 (31.7%)	23 (38.3%)

denotes statistically significant. +IDC: invasive duct carcinoma; +LVI: lymphovascular invasion; +M. subtype: molecular subtype; +TNBC: triple negative breast cancer.